文献速递高血压心力衰竭与心肌病

强化降压对高血压患者左心室肥厚的影响:SPRINT研究

Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
PubMed 文献 · Circulation · 2017-05-16

SPRINT试验纳入8164例无糖尿病的高血压患者,随机分为强化降压组(目标收缩压<120 mmHg)和标准降压组(目标收缩压<140 mmHg)。中位随访3.81年,强化降压组新发左心室肥厚风险降低46%(HR=0.54),已有左心室肥厚者逆转率提高66%(HR=1.66);校正左心室肥厚后,强化降压对心血管结局的获益未明显减弱。

要点

  • 强化降压(目标收缩压<120 mmHg)较标准降压(目标<140 mmHg)降低新发左心室肥厚风险46%。
  • 已有左心室肥厚者,强化降压使逆转/改善可能性增加66%。
  • 左心室肥厚改善不能解释强化降压带来的大部分心血管事件减少。

核心结论

  • 在无糖尿病的高血压患者中,强化降压(目标收缩压<120 mmHg)较标准降压(目标<140 mmHg)降低新发左心室肥厚风险并提高已有左心室肥厚的逆转率。
  • 左心室肥厚的改善未能解释强化降压在SPRINT试验中观察到的大部分心血管事件减少。

研究设计与样本

  • SPRINT试验事后分析,纳入8164例无糖尿病的高血压患者,平均年龄67.9岁,女性35.3%,黑人31.2%。
  • 4086例随机分配至强化降压组(目标收缩压<120 mmHg),4078例分配至标准降压组(目标收缩压<140 mmHg)。
  • 通过基线和每半年标准12导联心电图Cornell电压标准定义左心室肥厚,中位随访3.81年。

主要发现

  • 无基线左心室肥厚者(n=7559)中,强化降压组较标准降压组新发左心室肥厚风险降低46%(HR=0.54;95%CI 0.43-0.68)。
  • 有基线左心室肥厚者(n=605,7.4%)中,强化降压组较标准降压组左心室肥厚逆转/改善可能性增加66%(HR=1.66;95%CI 1.31-2.11)。
  • 以左心室肥厚作为时变协变量校正前后,强化降压对心血管事件的风险比分别为0.76(95%CI 0.64-0.90)和0.77(95%CI 0.65-0.91)。

临床怎么用

  • 对于无糖尿病的高血压患者,强化降压(目标收缩压<120 mmHg)可考虑用于预防新发左心室肥厚或促进已有左心室肥厚的逆转。
  • 强化降压对心血管事件的获益不能完全由左心室肥厚改善解释,提示其获益机制涉及其他途径。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is currently unknown whether intensive blood pressure (BP) lowering beyond that recommended would lead to more lowering of the risk of left ventricular hypertrophy (LVH) in patients with hypertension and whether reducing the risk of LVH explains the reported cardiovascular disease (CVD) benefits of intensive BP lowering in this population. METHODS: This analysis included 8164 participants (mean age, 67.9 years; 35.3% women; 31.2% blacks) with hypertension but no diabetes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial): 4086 randomly assigned to intensive BP lowering (target SBP <120 mm Hg) and 4078 assigned to standard BP lowering (target SBP <140 mm Hg). Progression and regression of LVH as defined by Cornell voltage criteria derived from standard 12-lead ECGs recorded at baseline and biannually were compared between treatment arms during a median follow-up of 3.81 years. The effect of intensive (versus standard) BP lowering on the SPRINT primary CVD outcome (a composite of myocardial infarction, acute coronary syndrome, stroke, heart failure, and CVD death) was compared before and after adjustment for LVH as a time-varying covariate. RESULTS: Among SPRINT participants without baseline LVH (n=7559), intensive (versus standard) BP lowering was associated with a 46% lower risk of developing LVH (hazard ratio=0.54; 95% confidence interval, 0.43-0.68). Similarly, among SPRINT participants with baseline LVH (n=605, 7.4%), those assigned to the intensive (versus standard) BP lowering were 66% more likely to regress/improve their LVH (hazard ratio=1.66; 95% confidence interval, 1.31-2.11). Adjustment for LVH as a time-varying covariate did not substantially attenuate the effect of intensive BP therapy on CVD events (hazard ratio of intensive versus standard BP lowering on CVD, 0.76 [95% confidence interval, 0.64-0.90] and 0.77 [95% confidence interval, 0.65-0.91] before and after adjustment for LVH as a time-varying covariate, respectively). CONCLUSIONS: Among patients with hypertension but no diabetes mellitus, intensive BP lowering (target systolic BP <120 mm Hg) compared with standard BP lowering (target systolic BP <140 mm Hg) resulted in lower rates of developing new LVH in those without LVH and higher rates of regression of LVH in those with existing LVH. This favorable effect on LVH did not explain most of the reduction in CVD events associated with intensive BP lowering in the SPRINT trial. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01206062.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Soliman EZ, Ambrosius WT, Cushman WC, et al. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017. PMID: 28512184. doi:10.1161/CIRCULATIONAHA.117.028441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。